Last reviewed · How we verify

Once-daily ABC+3TC — Competitive Intelligence Brief

Once-daily ABC+3TC (Once-daily ABC+3TC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI) combination. Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Once-daily ABC+3TC (Once-daily ABC+3TC) — Medical Research Council. ABC+3TC is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that blocks HIV reverse transcriptase to prevent viral replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Once-daily ABC+3TC TARGET Once-daily ABC+3TC Medical Research Council marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Reyataz + Epzicom Reyataz + Epzicom ViiV Healthcare marketed Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitors) HIV protease; HIV reverse transcriptase
TDF/3TC/EFV TDF/3TC/EFV Peking Union Medical College Hospital marketed Antiretroviral combination therapy (NRTI + NNRTI) HIV reverse transcriptase
Lamiduvine (Epivir) Lamiduvine (Epivir) Catholic University of the Sacred Heart marketed Nucleoside Reverse Transcriptase Inhibitor (NRTI) HIV reverse transcriptase
Doravirine + tenofovir DF + lamivudine Doravirine + tenofovir DF + lamivudine Instituto Mexicano del Seguro Social marketed Antiretroviral combination (NNRTI + NRTIs) HIV reverse transcriptase
Abacavir/lamivudine/zidovudine Abacavir/lamivudine/zidovudine Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections marketed Nucleoside reverse transcriptase inhibitor (NRTI) combination HIV reverse transcriptase
Zidovudine (drug) Zidovudine (drug) Johann Wolfgang Goethe University Hospital marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) combination class)

  1. Medical Research Council · 2 drugs in this class
  2. Bristol-Myers Squibb · 1 drug in this class
  3. Fundacion SEIMC-GESIDA · 1 drug in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Janssen Scientific Affairs, LLC · 1 drug in this class
  6. Merck Sharp & Dohme LLC · 1 drug in this class
  7. National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
  8. Tibotec, Inc · 1 drug in this class
  9. University of North Carolina, Chapel Hill · 1 drug in this class
  10. Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Once-daily ABC+3TC — Competitive Intelligence Brief. https://druglandscape.com/ci/once-daily-abc-3tc. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: